Interprotein

Executive Summary

Interprotein Corporation is a Japanese biotechnology company pioneering the development of modulators for protein-protein interaction (PPI) targets through its proprietary INTENDD® small molecule design platform and helix-loop-helix peptide libraries. By targeting previously intractable PPI interfaces, the company aims to unlock a new class of therapeutics that combine the specificity of biologics with the convenience of small molecules. Founded in 2020 and headquartered in Tokyo, Interprotein operates at the preclinical stage with a workforce of 10–50 employees, focusing on oncology and immunology. Its dual-platform approach enables the generation of high-affinity binders against challenging targets, offering potential patient-friendly alternatives to current biologic-based PPI inhibitors. Although the company has not yet disclosed total funding or valuation, its presence in the biopharmguy database indicates active engagement in the Japanese biotech ecosystem.

Upcoming Catalysts (preview)

• Q4 2026Lead Optimization Completion for Lead PPI Program70% success
• Q2 2027IND-Enabling Studies Initiation50% success
• Q3 2026Strategic Partnership or Licensing Deal40% success